Abstract
In August 2011 crizotinib (Xalkori; Pfizer), a small-molecule kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-positive, as detected by an FDA-approved test.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Janku, F. et al. Targeted therapy in non-small-cell lung cancer — is it becoming a reality? Nature Rev. Clin. Oncol. 7, 401–414 (2010).
Soda, M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–567 (2007).
McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389–3395 (2008).
Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408–4417 (2007).
Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition Factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342–6363 (2011).
US Food and Drug Administration. FDA labeling information — Xalkori. FDA website [online], (2011).
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
Camidge, D. R. et al. Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29, 2501 (2011).
Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004–1012 (2011).
Choi, Y, L. et al. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734–1739 (2010).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Alice T. Shaw has been a consultant for Pfizer, Chugai and Ariad.
Rights and permissions
About this article
Cite this article
Shaw, A., Yasothan, U. & Kirkpatrick, P. Crizotinib. Nat Rev Drug Discov 10, 897–898 (2011). https://doi.org/10.1038/nrd3600
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3600
This article is cited by
-
Synthesis of novel mono- and bis-pyrazolylthiazole derivatives as anti-liver cancer agents through EGFR/HER2 target inhibition
BMC Chemistry (2023)
-
Design, synthesis, and antiproliferative activities of novel thiazolyl-pyrazole hybrid derivatives
Medicinal Chemistry Research (2023)
-
Organocatalytic atroposelective construction of axially chiral N, N- and N, S-1,2-azoles through novel ring formation approach
Nature Communications (2022)
-
miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2
Molecular and Cellular Biochemistry (2018)
-
Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance
Cell Death & Disease (2017)
